All compounds
Libido
PT-141
Bremelanotide | Sexual Response
Typical Dose
0.5–2 mg
Route
Injectable
Variants
10mg
Overview
What is PT-141?
PT-141 (bremelanotide) is a melanocortin receptor agonist acting on central pathways to enhance sexual desire and arousal in both sexes.
Mechanism of Action
Selectively activates MC4R in the hypothalamus, increasing dopaminergic signaling related to sexual arousal.
Key Benefits
- Increased libido
- Improved arousal response
- Works centrally — not vascular
Research Indications
HSDD (low desire)Most Effective
ED researchEffective
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative | 0.5 mg | As needed | Subcutaneous |
| Standard starting dose | 1 mg | As needed | Subcutaneous |
| Typical maintenance | 1.5 mg | ≤2x weekly | Subcutaneous |
| Maximum | 2 mg | ≤2x weekly | Subcutaneous |
Peptide Interactions
Melanotan II
Antihypertensives
BP changes
Side Effects & Safety
Common Side Effects
- Nausea (most common)
- Flushing
- Transient BP increase
- Headache
Safety Guidelines
- For laboratory research use only — not for human consumption
- Store reconstituted vials at 2–8°C, use within 30 days
- Rotate injection sites to avoid local irritation
- Discontinue and consult a clinician if adverse reactions occur
Quality Indicators
- ≥95% purity verified by HPLC
- Third-party tested for sterility
- Lyophilized in sealed multi-dose vial
- Bacteriostatic water reconstitution
- Refrigerated cold-chain shipping
What to Expect
- 1Dose 1Effect within 1–4 hours
- 2Week 1–4Improved sexual response with periodic use
Need a different compound?
Browse all peptides